Cargando…
Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis
INTRODUCTION: Congenital heart disease (CHD) is one of the most prevalent birth defects in the world. The pathogenesis of CHD is complex and unclear. With the development of metabolomics technology, variations in metabolites may provide new clues about the causes of CHD and may serve as a biomarker...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677635/ https://www.ncbi.nlm.nih.gov/pubmed/36404327 http://dx.doi.org/10.1186/s12872-022-02912-2 |
_version_ | 1784833847008952320 |
---|---|
author | Yuan, Xuelian Li, Lu Kang, Hong Wang, Meixian Zeng, Jing Lei, Yanfang Li, Nana Yu, Ping Li, Xiaohong Liu, Zhen |
author_facet | Yuan, Xuelian Li, Lu Kang, Hong Wang, Meixian Zeng, Jing Lei, Yanfang Li, Nana Yu, Ping Li, Xiaohong Liu, Zhen |
author_sort | Yuan, Xuelian |
collection | PubMed |
description | INTRODUCTION: Congenital heart disease (CHD) is one of the most prevalent birth defects in the world. The pathogenesis of CHD is complex and unclear. With the development of metabolomics technology, variations in metabolites may provide new clues about the causes of CHD and may serve as a biomarker during pregnancy. METHODS: Sixty-five amniotic fluid samples (28 cases and 37 controls) during the second and third trimesters were utilized in this study. The metabolomics of CHD and normal fetuses were analyzed by untargeted metabolomics technology. Differential comparison and randomForest were used to screen metabolic biomarkers. RESULTS: A total of 2472 metabolites were detected, and they were distributed differentially between the cases and controls. Setting the selection criteria of fold change (FC) ≥ 2, P value < 0.01 and variable importance for the projection (VIP) ≥ 1.5, we screened 118 differential metabolites. Within the prediction model by random forest, PE(MonoMe(11,5)/MonoMe(13,5)), N-feruloylserotonin and 2,6-di-tert-butylbenzoquinone showed good prediction effects. Differential metabolites were mainly concentrated in aldosterone synthesis and secretion, drug metabolism, nicotinate and nicotinamide metabolism pathways, which may be related to the occurrence and development of CHD. CONCLUSION: This study provides a new database of CHD metabolic biomarkers and mechanistic research. These results need to be further verified in larger samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02912-2. |
format | Online Article Text |
id | pubmed-9677635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96776352022-11-22 Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis Yuan, Xuelian Li, Lu Kang, Hong Wang, Meixian Zeng, Jing Lei, Yanfang Li, Nana Yu, Ping Li, Xiaohong Liu, Zhen BMC Cardiovasc Disord Research INTRODUCTION: Congenital heart disease (CHD) is one of the most prevalent birth defects in the world. The pathogenesis of CHD is complex and unclear. With the development of metabolomics technology, variations in metabolites may provide new clues about the causes of CHD and may serve as a biomarker during pregnancy. METHODS: Sixty-five amniotic fluid samples (28 cases and 37 controls) during the second and third trimesters were utilized in this study. The metabolomics of CHD and normal fetuses were analyzed by untargeted metabolomics technology. Differential comparison and randomForest were used to screen metabolic biomarkers. RESULTS: A total of 2472 metabolites were detected, and they were distributed differentially between the cases and controls. Setting the selection criteria of fold change (FC) ≥ 2, P value < 0.01 and variable importance for the projection (VIP) ≥ 1.5, we screened 118 differential metabolites. Within the prediction model by random forest, PE(MonoMe(11,5)/MonoMe(13,5)), N-feruloylserotonin and 2,6-di-tert-butylbenzoquinone showed good prediction effects. Differential metabolites were mainly concentrated in aldosterone synthesis and secretion, drug metabolism, nicotinate and nicotinamide metabolism pathways, which may be related to the occurrence and development of CHD. CONCLUSION: This study provides a new database of CHD metabolic biomarkers and mechanistic research. These results need to be further verified in larger samples. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02912-2. BioMed Central 2022-11-20 /pmc/articles/PMC9677635/ /pubmed/36404327 http://dx.doi.org/10.1186/s12872-022-02912-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yuan, Xuelian Li, Lu Kang, Hong Wang, Meixian Zeng, Jing Lei, Yanfang Li, Nana Yu, Ping Li, Xiaohong Liu, Zhen Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title | Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title_full | Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title_fullStr | Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title_full_unstemmed | Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title_short | Biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
title_sort | biomarkers for isolated congenital heart disease based on maternal amniotic fluid metabolomics analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677635/ https://www.ncbi.nlm.nih.gov/pubmed/36404327 http://dx.doi.org/10.1186/s12872-022-02912-2 |
work_keys_str_mv | AT yuanxuelian biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT lilu biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT kanghong biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT wangmeixian biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT zengjing biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT leiyanfang biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT linana biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT yuping biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT lixiaohong biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis AT liuzhen biomarkersforisolatedcongenitalheartdiseasebasedonmaternalamnioticfluidmetabolomicsanalysis |